In the FERGI clinical study, addition of pictilisib to fulvestrant did not significantly improve PFS in ER+ advanced breast cancer resistant to treatment with an AI in the adjuvant or metastatic setting [35]. This evidence concerns the gene ESR1 and breast carcinoma.